menu
    • menu
    [{"orgOrder":0,"company":"Mediolanum Farmaceutici","sponsor":"ElsaLys Biotech","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"FRANCE","productType":"Antibody, Unconjugated","year":"2020","type":"Acquisition","leadProduct":"Inolimomab","moa":"Interleukin-2 receptor alpha chain","graph1":"Immunology","graph2":"Approved FDF","graph3":"Mediolanum Farmaceutici","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Mediolanum Farmaceutici \/ Mediolanum Farmaceutici","highestDevelopmentStatusID":"15","companyTruncated":"Mediolanum Farmaceutici \/ Mediolanum Farmaceutici"}]

    Find Clinical Drug Pipeline Developments & Deals by Mediolanum Farmaceutici

    Menu

    Mediolanum Farmaceutici

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Mediolanum Farmaceutici

                            Italy arrow
                            COMPAMED
                            Not Confirmed

                            Mediolanum Farmaceutici

                            Italy arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Inolimomab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Recipient : ElsaLys Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Mediolanum Farmaceutici Acquires the French Company ElsaLys Biotech to Develop Next Generation Immuno-oncology...

                            Details : Acquisition of ElsaLys Biotech adds drugs like Inolimomab and ELB011 to Mediolanum Farmaceutici's pipeline paving the way for its international expansion and increasing the Group's R&D capabilities.

                            Product Name : Leukotac

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 07, 2020

                            Lead Product(s) : Inolimomab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Recipient : ElsaLys Biotech

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth